Vistin Pharma ASA: Second quarter and YTD 2025 financial results

Oslo, Norway, 15th of August 2025

Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025.

Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue was driven by 17% higher sales volume. Revenue for first half of 2025 ended at MNOK 233 compared to MNOK 210 YTD last year, an increase of 11%.

Second quarter EBITDA ended at MNOK 30 compared to MNOK 27 in Q2 2024, representing 11% increase. EBITDA was positively affected by increased ...